News for NRX Pharmaceuticals Stock (NRXP)

Class Action Suit Against NRx Pharmaceuticals Dismissed

PRNewsWire • 06/22/22

Relief Reports that its U.S. Collaboration Partner has Announced an Update on Breakthrough Designation for Aviptadil

Accesswire • 06/13/22

NRx Pharmaceuticals Provides Update on Breakthrough Therapy Designation (BTD) Request for ZYESAMI® (aviptadil)

PRNewsWire • 06/11/22

NRx Pharmaceuticals Appoints Seth Van Voorhees, PhD, as Chief Financial Officer and Treasurer

PRNewsWire • 06/08/22

Hot Penny Stocks Under $1 To Watch In June

PennyStocks • 06/02/22

Why Is NRx Pharmaceuticals (NRXP) Stock Down 60% Today?

InvestorPlace • 05/26/22

Why NRX Pharmaceuticals Shares Are Trading Lower During Premarket On Thursday?

Benzinga • 05/26/22

Relief Reports that its U.S. Collaboration Partner Announces Data Safety Monitoring Board (DSMB) Update on the U.S. National Institutes of Health (NIH) Study of aviptadil in Critical COVID-19

Accesswire • 05/26/22

NRx Pharmaceuticals Announces Data Safety Monitoring Board (DSMB) Update on U.S. National Institutes of Health (NIH) Study of ZYESAMI® (aviptadil) in Critical COVID-19

PRNewsWire • 05/26/22

NRx Pharmaceuticals Leaders to Present at the H.C. Wainwright & Co. Global Investment Conference

PRNewsWire • 05/19/22

NRx Pharmaceuticals, Inc. (NRXP) CEO Robert Besthof on Q1 2022 Results - Earnings Call Transcript

Seeking Alpha • 05/16/22

NRx Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results

PRNewsWire • 05/16/22

NRx Pharmaceuticals Announces Enrollment of First Patient in Phase II Study of Bipolar Depression with Sub-Acute Suicidality

PRNewsWire • 05/12/22

NRx Pharmaceuticals to Report First Quarter 2022 Results on May 16, 2022

PRNewsWire • 05/10/22

NRX PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of NRx Pharmaceuticals, Inc. - NRXP

Business Wire • 05/05/22

Relief Reports that its U.S. Collaboration Partner has Filed a New Breakthrough Therapy Designation Request for Aviptadil

Accesswire • 04/22/22

NRx Pharmaceuticals Again Requests For FDA Breakthrough Therapy Status For COVID-19 Therapy

Benzinga • 04/21/22

NRx Pharmaceuticals Files New Breakthrough Therapy Designation Request for ZYESAMI® (aviptadil) in Subgroup of Patients with Critical COVID-19 with Respiratory Failure that were also treated with Remdesivir and continued to progress

PRNewsWire • 04/21/22

NRx Pharmaceuticals' Interim CEO and other Leaders to Present at 21st Annual Needham Virtual Healthcare Conference

PRNewsWire • 04/08/22

NRx Pharmaceuticals, Inc. (NRXP) CEO Robert Besthof on Q4 2021 Results - Earnings Call Transcript

Seeking Alpha • 03/31/22

NRx Pharma Says I-SPY Study Of Inhaled Zyesami In Critical COVID-19 Stopped

Benzinga • 03/31/22

NRx Pharmaceuticals Provides Business Update and Reports Full Year 2021 Financial Results

PRNewsWire • 03/31/22

NRx Pharmaceuticals to Report Year-End 2021 Results on March 31, 2022

PRNewsWire • 03/28/22

NRXP Monday Deadline: ROSEN, A Top Ranked Law Firm, Encourages NRx Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Monday Deadline in Securities Class Action - NRXP, NRXPW

Newsfile Corp • 03/19/22

Deadline Monday Reminder: The Schall Law Firm Encourages Investors in NRx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Newsfile Corp • 03/18/22